Amy Sion to Humans
This is a "connection" page, showing publications Amy Sion has written about Humans.
Connection Strength
0.140
-
Montelukast-Based Premedication Regimen for Recurrent Cetuximab Infusion-Related Reactions. JCO Oncol Pract. 2021 01; 17(1):54-56.
Score: 0.028
-
Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. J Oncol Pharm Pract. 2020 Jun; 26(4):861-865.
Score: 0.026
-
Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract. 2019 Dec; 25(8):1867-1872.
Score: 0.025
-
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018 06; 45(3):156-163.
Score: 0.025
-
Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biol Ther. 2006 Aug; 5(8):909-11.
Score: 0.011
-
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 04 10; 39(11):1274-1305.
Score: 0.007
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.006
-
A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics. J Oncol Pharm Pract. 2019 Jun; 25(4):847-854.
Score: 0.006
-
Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB). J Biol Chem. 2008 Oct 17; 283(42):28265-73.
Score: 0.003
-
CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007 Sep; 96(9):2224-31.
Score: 0.003